Form 8-K - Current report:
SEC Accession No. 0001628280-17-007877
Filing Date
2017-08-02
Accepted
2017-08-02 17:00:38
Documents
1
Period of Report
2017-08-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K - NEW DEBT AGREEMENT a8k-newdebtagreement.htm 8-K 25262
  Complete submission text file 0001628280-17-007877.txt   26495
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 171000987
SIC: 2834 Pharmaceutical Preparations